Trial Profile

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ladarixin (Primary) ; Sotorasib (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Aug 2023 Phase of the trial is changed form phase 1 to phase 1/2. "Progression Free Survival (PFS)" is added as a primary end-point , thus making "TU" also a trial focus.
07 Aug 2023 Status changed from not yet recruiting to recruiting.
07 Aug 2023 Planned End Date changed from 1 Jul 2026 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com